"She #39;s Happy" RMG #39;s next Stem Cell Miracle
Meet Mary Taylor, she was blind for four years from wet and dry Macular Degeneration. Her son Richard, was a previous patient of Regenerative Medical Group, as he received treatment for his...
By: iManifestart
Continued here:
"She's Happy" RMG's next Stem Cell Miracle - Video
Dog #39;s arthritis greatly helped by stem cell treatment
Lab with arthritis that made it hard to get up and go out to relieve himself received stem cell treatment at age of 9. Now 11, he keeps up with dogs half his...
By: Parkview Veterinary Hospital, Boonton NJ
Continued here:
Dog's arthritis greatly helped by stem cell treatment - Video
MIAMI (PRWEB) January 22, 2015
Regenestem, a division of the Global Stem Cells Group, Inc., has announced the launch of a new stem cell treatment center in Veracruz, Mexico. The new facility offers the most advanced protocols and techniques in cellular medicine to patients from around the world.
The opening of Regenestem Veracruz is in partnership with Eleuterio Arrieta, M.D., Director of Santa Teresita Hospital in Veracruz. Dr. Arrieta has extensive experience in management of chronic degenerative diseases with autologous stem cell therapies, expertise he will use to deliver cutting edge therapies and follow-up treatment under the Regenestem brand in Veracruz.
Under the direction of Global Stem Cells Group, Regenestem is expanding its clinical presence worldwide by partnering with qualified physicians experienced in stem cell therapies to open new clinics, licensed and developed under the Regenestem banner.
In 2014, Global Stem Cells Group expanded the Regenestem Networks presence to 20 countries, adding new state-of-the-art regenerative medicine facilities to the company's growing global presence.
Regenestem offers stem cell treatments to help with a variety of diseases and conditions including arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes, and pain due to injuries at various facilities worldwide. Regenestem Veracruz will have an international staff experienced in administering the leading cellular therapies available.
Regenestem is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. Regenestem clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.
The Global Stem Cells Group and Regenestem are committed to the highest of standards in service and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.
For more information, visit the Regenestem Network website, email info(at)regenstem(dot)com, or call 305-224-1858.
About Regenestem:
See the rest here:
Regenestem Network, a division of Global Stem Cells Group, Announces Launch of New Stem Cells and Regenerative ...
CTV.ca News Staff Published Monday, November 30, 2009 10:06AM EST Last Updated Saturday, May 19, 2012 12:22AM EDT
Montreal researchers are taking part in what could become a breakthrough in stem cell transplants, by leading the first transplant of a mismatched donor.
A 28-year-old father-to-be who has Ewing sarcoma is about to become the first person in North America to get a transplant from a mismatched donor.
The patient, Andrew Willette, needs the transplant to fight his cancer, but no one in his family is an appropriate match. So he will be using cells from his sister, who is only a partial match.
Usually, such transplants fail. That's because patients usually reject and attack the foreign donor cells. The ensuing response can kill the patient, or lead to infections or relapses.
But, the technique pioneered in a Montreal lab by Dr. Denis-Claude Roy of the Maisonneuve-Rosemont Hospital could change that.
Roy explains that his research team developed a new approach that preserves the cells that fight infection and disease while eliminating the cells that reject donor cells.
"We are letting Mother Nature decide which cells are going to react," he told CTV's Canada AM Monday morning.
Roy explains that the technique involves introducing donor cells to the patient cells in a lab.
"Those cells that recognize foreign patient cells become activated. The cells that are there to fight infections or viruses or even leukemia aren't activated, they don't see their target, so they're actually sleeping. So we then kill those cells that are activated," he explained.
Read this article:
New technique could revolutionize stem-cell transplants
IMAGE:Stem Cells and Development is an authoritative peer-reviewed journal published 24 times per year in print and online. The journal is dedicated to communication and objective analysis of developments in... view more
Credit: Mary Ann Liebert, Inc., publishers
New Rochelle, NY, January 20, 2015-- Multipotent cells isolated from the human umbilical cord, called mesenchymal stromal cells (hUC-MSCs) have shown promise for use in cell therapy to treat a variety of human diseases. However, intriguing new evidence shows that hUC-MSCs isolated from women with gestational diabetes demonstrate premature aging, poorer cell growth, and altered metabolic function, as reported in an article in Stem Cells and Development, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Stem Cells and Development website until February 17th, 2015.
Jooyeon Kim and coauthors from University of Ulsan College of Medicine, Kyung Hee University College of Medicine, and Seoul National University Bundang Hospital, Seoul, Korea, compared the growth and viability characteristics of hUC-MSCs from the umbilical cords of pregnant women with and without gestational diabetes. They evaluated cell growth, cellular senescence, mitochondrial function-related gene expression as a measure of metabolic activity, and the stem cells' ability to differentiate into various cell types such as bone and fat cells. They report their findings in the article "Umbilical Cord Mesenchymal Stromal Cells Affected by Gestational Diabetes Mellitus Display Premature Aging and Mitochondrial Dysfunction."
"We are only just beginning to scratch the surface of understanding how environmental and gestational stressors of all kinds affect stem cell populations," says Editor-in-Chief Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI. "The work described offers a non-invasive assay to help determine risk of developmental clinical vulnerability."
###
About the Journal
Stem Cells and Development is an authoritative peer-reviewed journal published 24 times per year in print and online. The Journal is dedicated to communication and objective analysis of developments in the biology, characteristics, and therapeutic utility of stem cells, especially those of the hematopoietic system. A complete table of contents and free sample issue may be viewed on the Stem Cells and Development website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cellular Reprogramming, Tissue Engineering, and Human Gene Therapy. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
See the article here:
Does gestational diabetes affect the therapeutic potential of umbilical cord-derived stem cells?
Amy Norton HealthDay Reporter Posted: Tuesday, January 20, 2015, 12:00 PM
TUESDAY, Jan. 20, 2015 (HealthDay News) -- A therapy that uses patients' own primitive blood cells may be able to reverse some of the effects of multiple sclerosis, a preliminary study suggests.
The findings, published Tuesday in the Journal of the American Medical Association, had experts cautiously optimistic.
But they also stressed that the study was small -- with around 150 patients -- and the benefits were limited to people who were in the earlier courses of multiple sclerosis (MS).
"This is certainly a positive development," said Bruce Bebo, the executive vice president of research for the National Multiple Sclerosis Society.
There are numerous so-called "disease-modifying" drugs available to treat MS -- a disease in which the immune system mistakenly attacks the protective sheath (called myelin) around fibers in the brain and spine, according to the society. Depending on where the damage is, symptoms include muscle weakness, numbness, vision problems and difficulty with balance and coordination.
But while those drugs can slow the progression of MS, they can't reverse disability, said Dr. Richard Burt, the lead researcher on the new study and chief of immunotherapy and autoimmune diseases at Northwestern University's Feinberg School of Medicine in Chicago.
His team tested a new approach: essentially, "rebooting" the immune system with patients' own blood-forming stem cells -- primitive cells that mature into immune-system fighters.
The researchers removed and stored stem cells from MS patients' blood, then used relatively low-dose chemotherapy drugs to -- as Burt described it -- "turn down" the patients' immune-system activity.
Read more here:
Early Study Says Stem Cells May Reverse Multiple Sclerosis Disability
Philadelphia, PA (PRWEB) January 20, 2015
Researchers developing technologies for high-speed eye exams, cancer treatment, stem cell growth and healthcare sanitation will receive a total of $650,000 in funding through the seventh round of the University City Science Centers QED Proof-of-Concept Program. The program, started in 2009, funds novel university technologies with market potential, bridging the gap between academic research and product commercialization. The awardees were selected from a pool of 68 applicants and nine universities in the Greater Philadelphia region.
The QED grants will support researchers at Lehigh University, Rutgers, The State University of New Jersey, Temple University and Thomas Jefferson University. Half of the $650,000 awarded will be contributed by the Science Center and half by the researchers institutions. Each project will also receive guidance from the Science Centers experienced team of business advisors. To date, 24 previously-funded QED projects have attracted $14.8 million in follow-on funding and led to six licensed technologies.
QED has received support from the U.S. Economic Development Administration, the Commonwealth of Pennsylvanias Ben Franklin Technology Development Authority, the Commonwealth of Pennsylvanias Department of Health, the Philadelphia Industrial Development Corporation, William Penn Foundation, and Wexford Science and Technology, a BioMed Realty Company.
QED continues to resonate with both the academic and funding community, says Science Center President and CEO Stephen S. Tang, Ph.D., MBA. The number of submissions continues to increase round over round as academic researchers identify ways to commercialize their emerging technologies. At the same time, the support of our funders enables us to continue to facilitate the development of these exciting technologies and contribute to the robust life science ecosystem in the Greater Philadelphia Region.
The Round 7 awardees include:
About the Science Center The University City Science Center is a dynamic hub for innovation, and entrepreneurship and technology development in the Greater Philadelphia region. It provides business incubation, programming, lab and office facilities, and support services for entrepreneurs, start-ups, and growing and established companies. The Science Center was the first, and remains the largest, urban research park in the United States. Since it was founded in 1963, graduate organizations and current residents of the University City Science Centers Port business incubators have created more than 15,000 jobs that remain in the Greater Philadelphia region today and contribute more than $9 billion to the regional economy annually. For more information about the Science Center, go to http://www.sciencecenter.org.
About the QED Program The QED Program was launched in April 2009. A common participation agreement that defines matching funds, indirect costs, and intellectual property management, has been signed by 21 universities and research institutions in Pennsylvania, New Jersey, and Delaware: The Childrens Hospital of Philadelphia, Delaware State University, Drexel University, Fox Chase Cancer Center, Harrisburg University of Science and Technology, Lankenau Institute for Medical Research, Lehigh University, Monell Chemical Senses Center, New Jersey Institute of Technology, The Pennsylvania State University, Philadelphia College of Osteopathic Medicine, Philadelphia University, Rowan University, Rutgers University, Temple University, Thomas Jefferson University, University of Delaware, University of Pennsylvania, University of the Sciences in Philadelphia, Widener University, and The Wistar Institute.
More here:
Four University Technologies Receive $650,000 from Science Centers QED Program
Stem Cell Therapy | Recent Strides Quell Stem Cell Debate
Ethical concerns for stem cells for arthritis could be mute...maybe. Reports show that adult stem cells (Autologous) have been shown in recent studies to have significant effects on osteoarthritis...
By: Nathan Wei
Read this article:
Stem Cell Therapy | Recent Strides Quell Stem Cell Debate - Video
Results from a preliminary study indicate that among patients with relapsing-remitting multiple sclerosis (MS), treatment with nonmyeloablative hematopoietic stem cell transplantation (low intensity stem cell transplantation) was associated with improvement in measures of disability and quality of life, according to a study in the January 20 issue of JAMA.
Fifty percent of patients with MS are unable to continue employment by 10 years from diagnosis or are unable to walk by 25 years. Despite an annual cost of approximately $47,000 per patient to treat MS, no therapy approved by the U.S. Food and Drug Administration has been shown to significantly reverse neurological disability or improve quality of life, according to background information in the article.
Multiple sclerosis is thought to be an immunemediated disorder of the central nervous system. Autologous (the use of one's own cells) hematopoietic (blood) stem cell transplantation (HSCT) is a form of immune suppression but unlike standard immune-based drugs, autologous HSCT is designed to reset rather than suppress the immune system. Richard K. Burt, M.D., of the Northwestern University Feinberg School of Medicine, Chicago, and colleagues studied the association of nonmyeloablative HSCT with neurological disability and other clinical outcomes in patients with relapsing-remitting MS (defined as acute relapses followed by partial or complete recovery and stable clinical manifestations between relapses; n = 123) or secondary-progressive MS (defined as a gradual progression of disability with or without superimposed relapses; n = 28) treated between 2003 and 2014.
Outcome analysis was available for 145 patients with an average follow-up of 2.5 years. On a measure of disability (Expanded Disability Status Scale [EDSS] score), there was significant improvement in 41 patients (50 percent of patients tested at 2 years) and in 23 patients (64 percent of patients tested at 4 years). "To our knowledge, this is the first report of significant and sustained improvement in the EDSS score following any treatment for MS," the authors write.
Receipt of HSCT was also associated with improvement in physical function, cognitive function and quality of life. There was also a reduction on another measure of clinical disease severity, volume of brain lesions associated with MS seen on magnetic resonance imaging (MRI). Four-year relapse-free survival was 80 percent and progression-free survival was 87 percent.
Patient selection is important in determining outcome, the researchers write. "In the post hoc analysis, the EDSS score did not improve in patients with secondary-progressive MS or in those with disease duration longer than 10 years."
The authors note the results are limited because this was an observational study without a control group. "Definitive conclusions will require a randomized trial; however, this analysis provides the rationale, appropriate patient selection, and therapeutic approach for a randomized study."
Editorial: Hematopoietic Stem Cell Transplantation for MS
Stephen L. Hauser, M.D., of the University of California, San Francisco, writes in an accompanying editorial that the study by Burt et al, taken together with other available evidence, enables several conclusions to be made with reasonable confidence.
"First, autologous HSCT does not appear to be effective against established progressive forms of MS and, absent new data, additional trials of these protocols are probably not indicated for patients with progressive MS. Second, immunosuppressive regimens that include HSCT appear to be effective against the relapsing-remitting form of MS, at least over several years of observation. However, it is by no means clear that the beneficial effects result from the infusion of stem cells rather than from the conditioning regimen. Given the availability of highly effective FDA-approved therapies against relapsing-remitting MS, it would seem reasonable to use these proven monotherapies in the clinical setting before considering complex HSCT regimens."
Follow this link:
Stem cell transplantation shows potential for reducing disability in patients with MS
Published: January 19, 2015
Sharon Nordstrom feels ashamed for participating in a $38,000 multiple sclerosis stem cell treatment inIndia that was not all it was promoted to be. Submitted photo.
JONATHAN CHARLTON THE STARPHOENIX
Sharon Nordstrom feels ashamed for participating in a $38,000 multiple sclerosis stem cell treatment inIndia that was not all it was promoted to be.
Im going to be a real mouthpiece now for people who think theyre toosmartto fall for stuff like this, she said.
The WinnipegFreePress this week published aninvestigationinto Winnipeg-based Regenetek Research, finding that head researcher Doug Broeska fabricated his credentials, including his PhD, and overstated the effects of the stem-cell treatment.
The newspaper also discovered that the chairman of the medical ethics committee at the Inamdar Hospital in Pune,India, told Broeska his lack of credentials and followup violatedinternational ethical standards and ordered him to step down as principal investigator of the stem-cell study.
Broeska told theFreePress he was terminated only because it was decided to have a local principal investigator stationed inIndia.
TheFreePress further reported that the University of Winnipeg has cancelled a joint stem-cell treatment project involving Broeskas company.
Nordstrom says she last heard from Broeska on June 16, when he said in an email he would expel her from the trial after she questioned the absence of a followup care plan. For months, she kept her situation quiet.
Read more:
Saskatoon woman snared in alleged fraudulent MS trial held in India